Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context and Evolving Inquiry

The legacy context of general health and science information has long served as a foundation for public understanding of medication benefits and risks. Within this broad framework, discussions around bisphosphonate therapies, such as Fosamax, have historically centered on their role in managing bone density disorders. As the informational landscape evolves, a more focused inquiry emerges: the potential association between Fosamax exposure and osteonecrosis of the jaw. This pivot requires shifting from generalized health education toward a targeted examination of exposure scenarios. In mass production environments, where workers may handle or be exposed to pharmaceutical compounds during manufacturing, the concern transitions from patient-oriented risk communication to occupational exposure assessment. The bridge concept here involves recognizing that the same compound, when encountered in industrial settings—through inhalation, dermal contact, or inadvertent ingestion—could pose distinct exposure pathways. This transition does not presuppose causation but rather reframes the question: from a general health audience asking about patient risk, to an occupational health perspective evaluating whether workplace exposure to Fosamax constitutes a relevant hazard for osteonecrosis of the jaw. The neutral academic tone preserves the inquiry as an open question, suitable for further investigation within occupational medicine and industrial hygiene frameworks.

Bridging from General Health to Occupational Exposure

The transition from general health information to occupational exposure assessment is critical. While patient-oriented discussions focus on therapeutic use, occupational settings may involve chronic low-level exposure through inhalation or dermal contact. This shift does not imply that occupational exposure causes ONJ, but it raises the question of whether such exposure pathways could contribute to risk. The same biological mechanisms that link Fosamax to ONJ in patients—namely, inhibition of osteoclast-mediated bone resorption leading to suppressed bone turnover—could theoretically apply to workers with sufficient systemic absorption. However, data on occupational exposure are lacking, and current evidence is derived from patient populations. Therefore, any assessment must rely on extrapolation from clinical data, acknowledging the uncertainties.

Fosamax and Osteonecrosis of the Jaw: Evidence and Risk Factors

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can lead to suppressed bone turnover. In the jawbone, which has a high remodeling rate, this suppression may impair the ability to repair microdamage and maintain bone health, particularly after dental procedures or infections. Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ can occur in patients taking Fosamax, the incidence in clinical trials was not significantly elevated compared to placebo, indicating that other factors may contribute to the development of ONJ.

Causation Considerations and Risk Management

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label recommends discontinuing use if severe symptoms develop, noting that most patients had relief of symptoms after stopping, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation-related considerations include the presence of known risk factors such as invasive dental procedures, cancer diagnosis, concomitant therapies, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The duration of bisphosphonate exposure is also a factor, as the risk of ONJ may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should be informed of these risks and advised to maintain good oral hygiene and undergo regular dental check-ups. If ONJ develops, management may include discontinuation of the bisphosphonate, antibiotic therapy, and surgical debridement, though the optimal approach is not well-defined. In summary, while Fosamax is associated with ONJ, the evidence indicates that the condition is rare and often occurs in the presence of additional risk factors. The prescribing information provides warnings and recommendations for risk mitigation, including consideration of drug discontinuation before invasive dental procedures. Patients and healthcare providers should weigh the benefits of Fosamax in reducing fracture risk against the potential risk of ONJ, particularly in those with pre-existing dental conditions or those undergoing dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ) in some patients. The prescribing information notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in clinical trials, the incidence was similar to placebo, suggesting that additional risk factors often contribute.

What are the risk factors for developing ONJ while on Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use may also increase risk.

How should patients on Fosamax manage dental health to reduce ONJ risk?

Patients should maintain good oral hygiene, have regular dental check-ups, and inform their dentist about Fosamax use. For invasive dental procedures, the prescribing information suggests that discontinuation of bisphosphonate treatment may reduce ONJ risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.